Astrazeneca Ab

Sven Hellberg

Stefan Berg

Ratan Bhat

Peter Soderman

Martin Nylöf

James Empfield

James Woods

Philip L Edwards

Yafeng Xue

Michael Thaddeus Klimas

Compounds of formula Ia or Ib wherein P; R; R; m; and n are as defined in the application, salts thereof, processed for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.

3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)

Selective phenyl substituted aminopyrazine inhibitors of GSK3 useful for the prevention and/or treatment of cognitive disorders.

Compounds having selective inhibiting effect at GSK3

The present invention relates to new compounds of formula (I) wherein Z is N; Y is CONR, NRCO, SONR, NRSO, CHNR, NR, NRCONR, CHCO, CO, O or CHO; X is CH or N; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing one or more atoms selected from C, N, O or S; Q is Calkyl, Calkenyl or Calkynyl, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, such as provide compounds having a selective inhibiting effect at GSK3. 

The present invention relates to new compounds of formula (I) wherein: Z is N and X is CH or N; Y is CONR; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S; Q is phenyl or a 5 or 6 membered aromatic heterocyclic ring containing one or more nitrogen atoms; R is CalkylNRRor Calkylazetidine; Ris hydrogen, Calkyl, Calkenyl, Calkynyl, CalkylCcycloalkyl, Calkylaryl, Calkylheteroaryl or CalkylNRR; Ris CalkylNRR, CalkylCcycloalkyl or Calkylheterocycloalkyl; as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy. 

The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy. 

3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3

The present invention relates to new compounds of the formula (I) a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, as well as intermediates used in the preparation of said active compounds 

Pyrimidine compounds

The present invention relates to new compounds of formula I wherein R, R, R, n, m are defined as in claim 1, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3 

Compounds in the treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3

The present invention relates to new compounds of formula (I) wherein Y, P, R, R, R, n, m are defined as in claim, a process for their preparation and new intermediates used therein, pharmaceutical composition containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related disease, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3 

Compounds for the treatment of dementia related diseases

An aqueous solution for prophylactic treatment of teats of lactating mammals, comprising as a first component at least partially deacetylated chitosan, or an acid addition salt thereof, in a concentration of up to about 2% by weight of chitosan, the solution having a pH of from about 4 to about 6.8, and said first component having a molecular weight such that the viscosity of the solution is less than about 50 mPas; and a method of prophylactic treatment of teats of lactating mammals.

2-arylamino-pyrimidines for the treatment of GSK3-related disorders

The present invention relates to a new compound of formula I as a free base or a pharmaceutically acceptable salt thereof, a process for the preparation, pharmaceutical formulations containing said therapeutically active compound and to the use of said compound in therapy. 

Growing community of inventors

Södertälje, Sweden

Sven Hellberg